Targeted Antibiotics Could Get Limited Data Approval Option From FDA
Executive Summary
Achaogen has designed a registration program with a single Phase III study for its next-generation aminoglycoside, plazomicin, to treat serious infections due to carbapenem-resistant Enterobacteriaceae, in what could be an interesting test for potential modifications to the standard approval pathway.
You may also be interested in...
Actavis Counting On Strong Product Line Depth For Avycaz Launch
The specialty pharma will take advantage of its presence in antibiotics to launch its third FDA-approved antibiotic for hard-to-treat infections before the end of the second quarter.
Actavis’ Avycaz Approval Shows How FDA Handles Limited-Data, Limited-Use Antibiotic
FDA grants approval to two of three indications for gram-negative antibiotic based on Phase II data but follows its advisors in rejecting a third indication that came without human data, offering hints of what the limitations and possibilities of a formal limited population antibiotic approval pathway might look like.
Actavis Avycaz Approval Shows How FDA Handles Limited-Data, Limited-Use Antibiotic
FDA grants approval to two of three indications for gram-negative antibiotic based on Phase II data, but follows it advisors in rejecting a third indication that came without human data, offering hints of what the limitations and possibilities of a formal limited population antibiotic approval pathway might be.